C Zheng1, T Shinomiya, C M Goldsmith, G Di Pasquale, B J Baum. 1. Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892-1190, USA.
Abstract
OBJECTIVES: Published studies of gene transfer to mouse salivary glands have not employed the parotid glands. Parotid glands are the likely target tissue for most clinical applications of salivary gene transfer. The purpose of the present study was to develop a convenient and reproducible method of retroductal gene transfer to mouse parotid glands. METHODS: The volume for vector delivery was assessed by infusion of Toluidine Blue into Stensen's ducts of Balb/c mice after direct intraoral cannulation. Recombinant, serotype 5 adenoviral vectors, encoding either firefly luciferase or human erythropoietin (hEpo), were constructed and then administered to parotid glands (10(7) vector particles/gland). Transgene expression in vivo was measured by enzyme activity (luciferase) or an enzyme-linked immunosorbent assay (hEpo). Vector biodistribution was measured by real-time quantitative (Q) PCR. RESULTS: The chosen volume for mouse parotid vector delivery was 20μL. Little vector was detected outside of the targeted glands, with both QPCR and luciferase assays. Transgene expression was readily detected in glands (luciferase, hEpo), and serum and saliva (hEpo). Most secreted hEpo was detected in saliva. CONCLUSION: These studies show that mouse parotid glands can be conveniently and reproducibly targeted for gene transfer, and should be useful for pre-clinical studies with many murine disease models.
OBJECTIVES: Published studies of gene transfer to mouse salivary glands have not employed the parotid glands. Parotid glands are the likely target tissue for most clinical applications of salivary gene transfer. The purpose of the present study was to develop a convenient and reproducible method of retroductal gene transfer to mouse parotid glands. METHODS: The volume for vector delivery was assessed by infusion of Toluidine Blue into Stensen's ducts of Balb/c mice after direct intraoral cannulation. Recombinant, serotype 5 adenoviral vectors, encoding either firefly luciferase or humanerythropoietin (hEpo), were constructed and then administered to parotid glands (10(7) vector particles/gland). Transgene expression in vivo was measured by enzyme activity (luciferase) or an enzyme-linked immunosorbent assay (hEpo). Vector biodistribution was measured by real-time quantitative (Q) PCR. RESULTS: The chosen volume for mouse parotid vector delivery was 20μL. Little vector was detected outside of the targeted glands, with both QPCR and luciferase assays. Transgene expression was readily detected in glands (luciferase, hEpo), and serum and saliva (hEpo). Most secreted hEpo was detected in saliva. CONCLUSION: These studies show that mouse parotid glands can be conveniently and reproducibly targeted for gene transfer, and should be useful for pre-clinical studies with many murine disease models.
Authors: A C O'Connell; L Baccaglini; P C Fox; B C O'Connell; D Kenshalo; H Oweisy; A T Hoque; D Sun; L L Herscher; V R Braddon; C Delporte; B J Baum Journal: Cancer Gene Ther Date: 1999 Nov-Dec Impact factor: 5.987
Authors: Seiichi Yamano; Li-Yun Huang; Chuantian Ding; John A Chiorini; Corinne M Goldsmith; Robert B Wellner; Basil Golding; Robert M Kotin; Dorothy E Scott; Bruce J Baum Journal: Hum Gene Ther Date: 2002-01-20 Impact factor: 5.695
Authors: A Voutetakis; C Zheng; A P Cotrim; F Mineshiba; S Afione; N Roescher; W D Swaim; M Metzger; M A Eckhaus; R E Donahue; C E Dunbar; J A Chiorini; B J Baum Journal: Gene Ther Date: 2009-09-17 Impact factor: 5.250
Authors: S Wang; B J Baum; S Yamano; M H Mankani; D Sun; M Jonsson; C Davis; F L Graham; J Gauldie; J C Atkinson Journal: J Dent Res Date: 2000-02 Impact factor: 6.116
Authors: E Y Ding; B L Hodges; H Hu; A J McVie-Wylie; D Serra; F K Migone; D Pressley; Y T Chen; A Amalfitano Journal: Hum Gene Ther Date: 2001-05-20 Impact factor: 5.695
Authors: Changyu Zheng; Nikolay P Nikolov; Ilias Alevizos; Ana P Cotrim; Shuying Liu; Linda McCullagh; John A Chiorini; Gabor G Illei; Bruce J Baum Journal: J Gene Med Date: 2010-01 Impact factor: 4.565
Authors: P Trionfini; S Tomasoni; M Galbusera; D Motto; L Longaretti; D Corna; G Remuzzi; A Benigni Journal: Gene Ther Date: 2009-08-13 Impact factor: 5.250
Authors: Jelle L Vosters; Hongen Yin; Nienke Roescher; Marc R Kok; Paul P Tak; John A Chiorini Journal: Arthritis Res Ther Date: 2009-12-14 Impact factor: 5.156
Authors: Changyu Zheng; Ana P Cotrim; Nikolay Nikolov; Fumi Mineshiba; William Swaim; Bruce J Baum Journal: Hum Gene Ther Methods Date: 2012-07-20 Impact factor: 2.396
Authors: Jomy J Varghese; Isaac L Schmale; Yuchen Wang; Mollie Eva Hansen; Shawn D Newlands; Catherine E Ovitt; Danielle S W Benoit Journal: J Vis Exp Date: 2018-05-03 Impact factor: 1.355
Authors: Simon D Tran; Younan Liu; Dengsheng Xia; Ola M Maria; Saeed Khalili; Renee Wan-Jou Wang; Vu-Hung Quan; Shen Hu; Jan Seuntjens Journal: PLoS One Date: 2013-04-24 Impact factor: 3.240